CELLINK brings on world distinguished scientist Dr. Mina J. Bisell to advisory board

Dr. MINA J. BISSELL is Distinguished Scientist, the highest rank bestowed at Lawrence Berkeley National Laboratory (LBNL) and serves as Senior Advisor to the Laboratory Director on Biology. She is also Faculty of four Graduate Groups in UC Berkeley: Comparative Biochemistry, Endocrinology, Molecular Toxicology, and Bioengineering (UCSF/UCB joint program). Having challenged several established paradigms, Bissell is a pioneer in breast cancer research and her body of work has provided much impetus for the current recognition of the significant role that extracellular matrix (ECM) signaling and microenvironment play in gene expression regulation in both normal and malignant cells. Her laboratory developed novel 3D assays and techniques that demonstrate her signature phrase: after conception, “phenotype is dominant over genotype.”

Dr. Mina J. Bisell will contribute to CELLINKs development within cancer research and focus on developing technologies advancing the field. The advisory board now consist of 4 advisors including, Rolf Claesson whom served as Chairman of Bayer HealthCare and Tecan Group, CEO of Bayer Diagnostics, executive management positions within Pharmacia, director of Hill-Rom and Supervisory Board member of Fresenius Medical Care, Dr. Ali Khademhosseini, whom served as Professor at Harvard-MIT, Brigham and Women’s Hospital and Harvard Medical School. Leads a satellite laboratory at the World Premier International-Advanced Institute for Materials Research at Tohoku University, Japan. Now appointed professor at UCLA. And Dr. David Williams, Professor at Wake Forest School of Medicine and is regarded as a leading authority on biomaterials, medical devices, and biocompatibility. Authored and co-authored over 400 technical papers within his field of expertise

For further information, please contact:

Erik Gatenholm, CEO                                                                               Gusten Danielsson, CFO

Phone: +46 73 267 00 00                                                                        Phone: +46 70 991 86 04

E-mail: [email protected]                                                                          E-mail: [email protected]


CELLINK is the first bioink company in the world and the leading 3Dbioprinter provider that focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic treatments. Founded 2016 and active in more than 45 countries, CELLINK is changing the future of medicine as we know it. To read more about CELLINK, please visit: www.cellink.com  

Latest press releases